A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients

A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients

We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spik...

Full description

Bibliographic Details
Main Authors:	Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Hiroya Ichikawa, Hironori Sakai, Wataru Hojo, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, Shigeki Nagao, Akihito Kitao, Yoshiharu Miyata, Taiji Koyama, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	Vaccines
Subjects:	SARS-CoV-2 vaccination allogeneic hematopoietic stem cell transplantation BNT162b2 mRNA-1273 COVID-19 vaccination
Online Access:	https://www.mdpi.com/2076-393X/10/11/1830

Similar Items

The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
by: Marika Watanabe, et al.
Published: (2022-01-01)

BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
by: Anna Kaznadzey, et al.
Published: (2022-04-01)

Risk of herpes zoster following mRNA COVID-19 vaccine administration
by: Ana Florea, et al.
Published: (2023-12-01)

From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community
by: Melinda C. Joyce, et al.
Published: (2022-12-01)

Key Lessons from COVID-19: A Narrative Review Describing Qatar’s Multifactorial Approach in Executing a Vaccination Campaign
by: Soha Albayat, et al.
Published: (2023-05-01)

Acquired hemophilia A (AHA) due to anti‐SARS‐CoV‐2 vaccination: A systematic review
by: Fnu Amisha, et al.
Published: (2023-05-01)

Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients
by: Takeo Nakajima, et al.
Published: (2022-08-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study
by: Soledad González, et al.
Published: (2022-09-01)

Safety and efficacy of RNA vaccines: State of the art
by: A. V. Blagov, et al.
Published: (2021-11-01)

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
by: Chiranjib Chakraborty, et al.
Published: (2021-07-01)

Durability of Protection Post–Primary COVID-19 Vaccination in the United States
by: Amanda Zheutlin, et al.
Published: (2022-09-01)

Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review
by: SeyedAhmad SeyedAlinaghi, et al.
Published: (2022-05-01)

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
by: Hagit Kopel, et al.
Published: (2023-11-01)

Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
by: Khalid Hajissa, et al.
Published: (2021-08-01)

Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies
by: Shuailei Chang, et al.
Published: (2022-03-01)

Data Resource Profile: COVid VAXines Effects on the Aged (COVVAXAGE)
by: Kaleen Hayes, et al.
Published: (2023-10-01)

Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study
by: Abanoub Riad, et al.
Published: (2021-10-01)

Characteristics and outcomes of adverse events after COVID‐19 vaccination
by: Tariq Kewan, et al.
Published: (2021-10-01)

The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines
by: Monika Skorupa, et al.
Published: (2022-03-01)

Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees
by: Gabriele Anichini, et al.
Published: (2022-05-01)

Protection against MIS-C outweighs the risk of myocarditis after Covid-19 vaccination in children
by: Marcello Mariani, et al.
Published: (2022-08-01)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
by: Eun-Ju Kim, et al.
Published: (2023-06-01)

Is a single COVID-19 vaccine dose enough in convalescents ?
by: Daniele Focosi, et al.
Published: (2021-09-01)

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
by: Miriam Echaide, et al.
Published: (2023-03-01)

Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals
by: Susan L. Uprichard, et al.
Published: (2022-02-01)

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
by: Farah M. Shurrab, et al.
Published: (2022-01-01)

Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
by: Daniele Focosi, et al.
Published: (2022-11-01)

Temporal association between COVID-19 vaccination and Raynaud’s phenomenon: A case series
by: Marcus Lisy, et al.
Published: (2023-01-01)

Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
by: Cynthia M. Rohde, et al.
Published: (2023-02-01)

Concomitant Peripheral and Pulmonary Arterial Thromboembolism 35 Days After SARS-CoV-2 mRNA Vaccine
by: Ahmet Can Topçu, et al.
Published: (2023-04-01)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
by: Maria Eduarda Andrade e Andrade, et al.
Published: (2022-01-01)

Sex Differences in Serious Adverse Events Reported Following Booster Doses of COVID-19 Vaccination in Thailand: A Countrywide Nested Unmatched Case-Control Study
by: Chawisar Janekrongtham, et al.
Published: (2023-11-01)

Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants
by: Nigam H. Padhiar, et al.
Published: (2022-05-01)

SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review
by: Caterina Ledda, et al.
Published: (2022-01-01)

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
by: Passakorn Wanchaijiraboon, et al.
Published: (2023-02-01)

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
by: Catherine E. Raptis, et al.
Published: (2022-10-01)

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
by: Giulia Vivaldi, et al.
Published: (2022-11-01)

Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV
by: Wang-Da Liu, et al.
Published: (2022-12-01)

Recipient-Reported Reactogenicity of Different SARS-CoV-2 Vaccination Regimens among Healthcare Professionals and Police Staff in Germany
by: Katharina Rau, et al.
Published: (2023-06-01)